Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

APOLLO-BC: Advanced Perfused platform for Breast Cancer therapy-response prediction

Obiettivo

The limited ability of preclinical models to predict clinical responses remains a major barrier in oncology drug development. Current systems used for cancer drug evaluation, including conventional 2D cultures and advanced 3D models such as patient-derived organoids (PDOs), fail to control key tumour microenvironment (TME) parameters that influence drug penetration, adaptive resistance, and therapeutic response, potentially limiting predictive accuracy. Consequently, a gap persists between preclinical efficacy and clinical response, highlighting the need for ex vivo systems with improved predictive performance. Breast cancer provides a clinically relevant setting to address this challenge. Subtypes such as TNBC and HER2-positive disease show substantial variability in response to approved therapies, creating a need for improved methods to prioritise treatment options. APOLLO-BC tests whether controlling key tumour microenvironment parameters, specifically perfusion and mechanical stiffness, improves the predictive accuracy of therapy-response ranking compared with PDO systems. The project will generate the first controlled direct comparative validation of a perfused, stiffness-controlled tumour model against conventional PDO workflows using matched patient-derived samples. A microfluidic platform integrating bioprinted 3D tumour constructs and real-time environmental monitoring will be standardised, followed by generation of matched TNBC and HER2+ models and a benchmarking study across ≥40 patients, each tested with ≥6 approved therapeutic regimens. Reproducibility and predictive concordance with retrospective clinical outcomes will be quantitatively compared with PDO workflows.
By generating rigorous comparative evidence, APOLLO-BC will determine whether microenvironmental engineering improves predictive drug-response assessment in breast cancer models, establishing a validated framework for next-generation functional oncology platforms.

Campo scientifico (EuroSciVoc)

Questo progetto non è ancora stato classificato con EuroSciVoc.
Suggerisci i campi scientifici che ritieni più rilevanti e aiutaci a migliorare il nostro servizio di classificazione.

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2026-POC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

FACULDADE DE CIENCIAS E TECNOLOGIADA UNIVERSIDADE NOVA DE LISBOA
Contributo netto dell'UE
€ 150 000,00
Indirizzo
QUINTA DA TORRE
2829 516 Caparica
Portogallo
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Beneficiari (1)